# Drug of interest
My drug of interest is Capreomycin.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. ABCC2 (z: 4.02)
2. ABCB1 (z: 1.85)
3. ABCC3 (z: 1.41)
4. ABCC4 (z: 0.86)
5. ABCC5 (z: 0.65)
6. ABCG2 (z: 0.6)
7. SLCO1B1 (z: 0.49)
8. HFE (z: 0.48)
9. MT-RNR1 (z: 0.45)
10. SLC22A16 (z: 0.45)
11. CBR1 (z: 0.44)
12. CYP2D7 (z: 0.44)
13. CDA (z: 0.43)
14. DCK (z: 0.37)
15. ABCB4 (z: 0.36)
16. HLA-B (z: 0.36)
17. HLA-DRB1 (z: 0.35)
18. SLC19A1 (z: 0.35)
19. G6PD (z: 0.34)
20. MTHFR (z: 0.34)
21. ABCC11 (z: 0.33)
22. CTPS1 (z: 0.32)
23. CYP2D6 (z: 0.31)
24. ABCC1 (z: 0.31)
25. CYP3A4 (z: 0.3)
26. HLA-C (z: 0.29)
27. HLA-A (z: 0.28)
28. ABCB7 (z: 0.27)
29. ABCC12 (z: 0.27)
30. SLC28A3 (z: 0.26)
31. HLA-DRA (z: 0.26)
32. ABCB6 (z: 0.25)
33. SLC22A8 (z: 0.25)
34. HLA-DQB1 (z: 0.25)
35. SLC13A1 (z: 0.24)
36. CBR3 (z: 0.24)
37. HLA-DPB1 (z: 0.23)
38. MT-ND1 (z: 0.23)
39. SLC22A6 (z: 0.23)
40. GGH (z: 0.23)
41. HCP5 (z: 0.23)
42. SLC22A15 (z: 0.22)
43. SLC22A11 (z: 0.22)
44. MTRR (z: 0.21)
45. TPMT (z: 0.21)
46. CYP2C19 (z: 0.21)
47. HLA-E (z: 0.2)
48. SLC28A1 (z: 0.2)
49. ADA (z: 0.2)
50. ALPL (z: 0.2)

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**Capreomycin**: The efficacy and toxicity of Capreomycin, an atypical aminoglycoside used against Mycobacterium tuberculosis, can be influenced by genetic variations in genes related to protein synthesis and ion transport, and drug handling genes like MDR1 and SLC22A2, which may impact drug uptake and excretion. Genes such as MT-RNR1, associated with aminoglycoside-induced hearing loss, might also influence Capreomycin's side effects like nephrotoxicity and ototoxicity.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**ABCC2**: ABCC2 gene variants influence the function of the MRP2 protein, affecting the pharmacokinetics and therapeutic outcomes of various drugs. For example, genetic variations like c.1249G>A and c.3972C>T can alter the excretion and plasma concentrations of drugs such as methotrexate, mycophenolate mofetil, tacrolimus, rosuvastatin, and others including irinotecan and docetaxel, thereby impacting drug effectiveness and toxicity. Non-pharmacokinetic interactions involve drugs like clopidogrel and sorafenib, which may affect therapeutic outcomes through MRP2-related pathways.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**ABCC3**: The ABCC3 gene significantly influences the pharmacokinetics and pharmacodynamics of drugs such as methotrexate and morphine by affecting their transport. Variants in ABCC3 can lead to altered excretion of methotrexate, which affects its effectiveness and side effects, and can modify the transport of morphine and its metabolites, impacting their systemic and neurological effects. Other chemotherapy drugs like doxorubicin and vincristine may also interact with ABCC3, potentially influencing drug efficacy and resistance through effects on drug efflux.

**ABCC4**: ABCC4 gene variants influence the pharmacokinetics and efficacy of various drugs by modulating their efflux from cells, which impacts drug concentrations in the body. This gene affects a wide range of drugs including cancer treatments (doxorubicin, methotrexate), antiretrovirals (zidovudine, tenofovir), and medications used in cardiovascular diseases and immune disorders (clopidogrel, azathioprine), potentially leading to variable therapy outcomes and drug resistance.

**ABCC5**: ABCC5, an efflux transporter gene, influences the pharmacokinetics and pharmacodynamics of several drugs, notably altering the bioavailability and systemic toxicity of doxorubicin, a key cancer chemotherapy drug. Other drugs such as glyburide, leucovorin, cannabidiol, irinotecan, and fluorouracil are also likely affected by ABCC5's capacity to modulate drug levels, either impacting their therapeutic efficacy or altering their toxicity profile.

**ABCG2**: ABCG2, a gene encoding an efflux transporter, significantly influences the pharmacokinetics of various drugs by altering their absorption, distribution, and excretion, impacting the effectiveness and required dosages of medications like rosuvastatin, chemotherapy agents (topotecan, methotrexate), tyrosine kinase inhibitors (sunitinib, imatinib), antiretrovirals (tenofovir), and cardiovascular drugs (atorvastatin, apixaban). Variants such as Q141K in the ABCG2 gene can further modify these drug interactions, necessitating adjustments in drug therapies to ensure optimal efficacy and safety.

**SLCO1B1**: The SLCO1B1 gene, which facilitates the hepatic uptake of drugs, exhibits polymorphisms like c.521T>C that affect the pharmacokinetics of multiple drugs including statins, repaglinide, and rifampin, potentially leading to increased drug plasma concentrations, altered efficacy, and toxicity. This variability in drug transport efficiency necessitates adjustments in dosing to optimize therapeutic outcomes and minimize adverse effects for drugs such as simvastatin, atorvastatin, and others.

**HFE**: Epoetin alfa, used for anemia in chronic kidney disease, interacts with HFE gene variants, affecting iron utilization and metabolism, thereby influencing the drug's pharmacokinetics. Conversely, pazopanib, a cancer therapy drug, may have non-pharmacokinetic interactions with the HFE gene by affecting iron metabolic pathways, though the exact mechanism is less clear.

**MT-RNR1**: The MT-RNR1 gene mutation m.1555A>G heightens susceptibility to ototoxic effects from aminoglycoside antibiotics such as gentamicin and tobramycin due to increased sensitivity of the mitochondrial ribosome, leading to impaired protein synthesis in cochlear cells and increasing the risk of irreversible hearing loss. The interaction between MT-RNR1 and aminoglycosides is pharmacodynamic as it influences the drug's action on the mitochondrial ribosome, rather than affecting the drug's metabolism or disposition.

**SLC22A16**: SLC22A16 plays a critical role in the pharmacokinetics of doxorubicin, a chemotherapeutic drug, by affecting its transport and thereby influencing the drug's efficacy and potential for cardiac toxicity. Although primarily involved with doxorubicin, SLC22A16 may also affect other chemotherapy drugs like fluorouracil and cyclophosphamide, potentially altering their metabolism or mechanisms of action rather than their transport.

**CBR1**: CBR1 notably affects the metabolism of chemotherapeutic drugs such as doxorubicin and daunorubicin by reducing them into less active compounds like doxorubicinol, thereby potentially altering their effectiveness and toxicity, particularly influencing cardiotoxicity risks. Genetic variants in CBR1 can lead to varied metabolism rates, impacting drug plasma levels and toxicity, while its interactions with other drugs like fluorouracil and cyclophosphamide, though less definitively understood, suggest modifications in drug efficacy and safety through carbonyl reduction.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**CDA**: The activity of the CDA gene, which encodes for the enzyme cytidine deaminase, is crucial in the metabolism of some chemotherapeutic drugs, particularly nucleoside analogs like cytarabine and gemcitabine. Genetic variations in CDA can lead to different enzyme activities that affect drug concentration and active metabolite levels, thereby impacting both the efficacy and toxicity of these drugs; for example, reduced enzyme activity can increase drug plasma levels, heightening the risk of myelosuppression and hepatotoxicity.

**DCK**: Deoxycytidine Kinase (DCK) is fundamental in the metabolism of anticancer drugs like gemcitabine and cytarabine, as variations in the DCK gene affect the transformation of these drugs into their active forms, pivotal for their effectiveness and potential resistance in cancer treatment. For gemcitabine and the ara-CTP metabolite of cytarabine, DCK facilitates their activation through phosphorylation processes, influencing drug efficacy and toxicity in treatments for cancers such as pancreatic, breast, non-small cell lung cancers, and leukemias.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**HLA-B**: The HLA-B gene plays a crucial role in drug hypersensitivity reactions through allele-specific interactions, such as the HLA-B*57:01 allele causing severe reactions to abacavir and the HLA-B*15:02 allele being associated with severe adverse reactions to carbamazepine. These interactions, which involve the immune system's response to drug-modified peptides or the drug itself presented by the HLA-B protein, emphasize the importance of genetic testing in precision medicine to tailor drug therapy and minimize adverse reactions based on individual genetic profiles.

**HLA-DRB1**: The HLA-DRB1 gene, through its various alleles, significantly influences the pharmacogenetic interactions that affect the efficacy and safety of medications, causing immune-mediated hypersensitivity reactions. For instance, the HLA-DRB1*15:01 allele is linked to abacavir hypersensitivity in HIV treatment, while HLA-DRB1*07:01 is associated with hepatic injuries from ximelagatran, highlighting the importance of understanding a patient's HLA-DRB1 allele status to optimize and personalize treatment strategies.

**SLC19A1**: The gene SLC19A1, which encodes a folate transporter protein, significantly influences the pharmacokinetics of antifolate medications such as methotrexate by affecting its cellular uptake, thus altering drug efficacy and toxicity. Variants in SLC19A1 can lead to differences in methotrexate transport into cells, impacting the necessity for personalized dosing strategies, and potentially affecting other similar chemotherapy drugs, although the extent of interaction may vary.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**MTHFR**: MTHFR genetic variants impact the efficacy and toxicity of drugs like folic acid, methotrexate, and capecitabine by affecting folate metabolism and homocysteine levels. Folic acid supplementation can address elevated homocysteine levels, while MTHFR mutations can alter methotrexate processing and enhance or reduce capecitabine activation, influencing drug dosages and resulting pharmacodynamic outcomes. Additionally, drugs such as phenytoin and carbamazepine exhibit non-metabolic interactions with MTHFR variants through effects on folate homeostasis, which may affect drug effectiveness and side-effect profiles.

**ABCC11**: The ABCC11 gene, known for facilitating ATP-dependent transport across cellular membranes, significantly affects the pharmacokinetics of anticancer drugs like fluorouracil and capecitabine by varying the efficiency of drug metabolite expulsion from cells. Different ABCC11 genetic variants lead to changes in drug bioavailability and toxicity, which affects the efficacy and side effects experienced by patients, making it pivotal for customizing cancer treatment protocols.

**CTPS1**: CTPS1, important in nucleotide synthesis, impacts the metabolism and effectiveness of the chemotherapy drug ara-CTP, a cytarabine metabolite. Variations in CTPS1 activity affect the balance of nucleotides such as CTP, influencing how ara-CTP, which inhibits DNA polymerases, competes with natural nucleotides, impacting its efficacy and toxicity in cancer therapy.

**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**ABCC1**: ABCC1, a critical gene encoding for an efflux transporter, significantly affects the pharmacokinetics and pharmacodynamics of various drugs by impacting their absorption, distribution, and elimination. Notably, it modulates the clearance of anticancer drugs like SN-38 and doxorubicin from cells, contributing to drug resistance and variability in therapeutic efficacy and toxicity, which is particularly relevant in optimizing cancer chemotherapy. Other drugs such as vincristine, methotrexate, and ritonavir, among others, also demonstrate pharmacogenetic interactions with ABCC1, affecting treatment outcomes especially in oncology.

**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**HLA-C**: HLA-C plays a crucial role in drug hypersensitivity reactions, primarily through immune response mechanisms influenced by its polymorphic nature. The presence of the HLA-C*06:02 allele, for example, is strongly associated with hypersensitivity to abacavir, used in HIV treatment, necessitating genetic screening to prevent severe reactions. Other drugs such as carbamazepine, allopurinol, clozapine, and phenytoin also show interactions with various HLA alleles that might contribute to adverse reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis.

**HLA-A**: The HLA-A gene is crucial in pharmacogenetic interactions due to its role in immune-mediated hypersensitivity reactions to certain drugs. For instance, the HLA-A*31:01 allele increases the risk of severe skin reactions to carbamazepine, while the HLA-A*02:01 allele is linked to severe adverse reactions to allopurinol, both through mechanisms involving the immune system's response to these drugs or their metabolites. Other drugs such as abacavir, phenytoin, and flucloxacillin among others are also implicated in similar immune responses based on the HLA-A gene variations, affecting drug pharmacodynamics rather than pharmacokinetics.

**ABCB7**: Vitamin B6 (pyridoxine) supplementation in patients with disorders such as X-linked sideroblastic anemia and ataxia, which involve the ABCB7 gene, may benefit mitochondrial function or enhance the residual activity of pathways dependent on ABCB7. This supplementation does not affect ABCB7 gene expression or protein function directly, but rather helps offset the impacts of its deficiency.

**ABCC12**: The ABCC12 gene, though part of the ABC transporter family known for drug transport and resistance roles, particularly in oncology, has no well-documented interactions with clinical drugs. Its potential influence on the effectiveness and distribution of anticancer drugs remains theoretical and speculative, with no direct evidence linking ABCC12 to specific pharmacogenetic impacts on drug response, metabolism, or resistance in existing literature.

**SLC28A3**: The gene SLC28A3, which is vital for the transport of nucleoside and nucleotide analog drugs, significantly impacts the pharmacokinetics of these medications by affecting their absorption, distribution, and elimination. Specifically, it transports ara-CTP, the active metabolite of cytarabine (used in cancer chemotherapy), into cells, influencing the drug's efficacy and toxicity. This interaction suggests that variations in SLC28A3 could lead to different treatment outcomes in patients, potentially affecting the therapeutic dosing of other similar drugs used in treatments for cancers and viral infections.

**HLA-DRA**: The HLA-DRA gene, though not directly interacting with drugs through pharmacokinetic pathways, plays an indirect role in pharmacodynamics due to its involvement in the immune system. It is implicated in the immune-mediated drug reactions, such as hypersensitivities to antibiotics like amoxicillin, flucloxacillin, and clavulanate, possibly by affecting how drug-related antigens are presented to the immune system by antigen-presenting cells, thereby influencing the likelihood or severity of allergic reactions.

**ABCB6**: ABCB6 mutations impact the pharmacokinetics of drugs like cyclophosphamide and doxorubicin by affecting their absorption into cells and intracellular storage, which influences the drugs’ effectiveness and toxicity. This variation in drug handling due to ABCB6 can significantly alter the therapeutic efficacy and side effects of these chemotherapeutic agents, underscoring the importance of genetic considerations in cancer treatment planning.

**SLC22A8**: Cefotaxime's clearance is influenced by genetic variations in the SLC22A8 gene, which encodes the Organic Anion Transporter 3 (OAT3) responsible for its renal excretion. These variations can lead to altered drug levels in the body, thereby affecting the efficacy and safety of cefotaxime, particularly in patients with renal impairment.

**HLA-DQB1**: HLA-DQB1 gene variants significantly impact drug hypersensitivity reactions, particularly for drugs like abacavir, allopurinol, nevirapine, lamotrigine, and carbamazepine, which can cause severe reactions such as Steven-Johnson syndrome and toxic epidermal necrolysis in genetically predisposed individuals. These interactions emphasize the role of HLA-DQB1 in pharmacodynamics, affecting drug safety and efficacy rather than drug metabolism.

**SLC13A1**: The gene SLC13A1, which encodes a sodium/sulfate symporter, influences the metabolism and excretion of drugs that undergo sulfate conjugation, such as acetaminophen and certain non-steroidal anti-inflammatory drugs (NSAIDs). Variations in SLC13A1 could potentially alter the pharmacokinetic profiles, including the clearance rates, of these drugs, leading to differences in drug efficacy and toxicity based on individual genetic makeup.

**CBR3**: CBR3, an enzyme involved in metabolizing drugs by reducing carbonyl groups to alcohols, significantly influences the pharmacokinetics of the chemotherapy drug doxorubicin, altering its efficacy and toxicity due to genetic variations such as CBR3 V244M. This variation affects how different individuals process doxorubicin, potentially necessitating customized dosage adjustments. Furthermore, CBR3 might interact similarly with other chemotherapy agents like docetaxel and paclitaxel, impacting their plasma concentrations and therapeutic effects.

**HLA-DPB1**: HLA-DPB1, a gene expressed in antigen-presenting cells, primarily affects drug hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) through immune modulation, particularly in pharmacodynamic interactions. For example, its specific alleles may increase the risk of agranulocytosis in patients treated with the antipsychotic drug clozapine, while there is no confirmed pharmacogenetic interaction between HLA-DPB1 and aspirin.

**MT-ND1**: Genetic variations in the MT-ND1 gene, which is involved in mitochondrial energy metabolism, can enhance the risk of severe side effects when interacting with certain drugs. Antiretroviral drugs like Zidovudine may increase mitochondrial toxicity in individuals with MT-ND1 mutations, while aminoglycoside antibiotics such as gentamicin can exacerbate ototoxicity and nephrotoxicity due to their effect on mitochondrial protein synthesis. This highlights the pharmacodynamic interactions where drugs can worsen the impact of dysfunctional mitochondrial Complex I, particularly in tissues with high energy demands.

**SLC22A6**: The SLC22A6 gene, or OAT1, plays a significant role in the renal clearance of drugs such as tenofovir, adefovir dipivoxil, and cidofovir by mediating their transport into the urine, which is crucial for controlling drug levels in the body. Variants in SLC22A6 can affect the transport efficiency of these antiviral agents, leading to different blood concentrations, potentially impacting therapeutic effectiveness and increasing the risk of nephrotoxicity and other side effects.

**GGH**: Variants in the GGH gene, which is essential in folate metabolism, alter enzyme activity, affecting the pharmacokinetics of antifolate drugs such as methotrexate. These interactions impact drug toxicity and effectiveness, necessitating individualized dosage adjustments to optimize treatment outcomes in cancer and autoimmune diseases. Additionally, it is speculated that GGH could influence other drugs like methylphenidate and pemetrexed, which are also dependent on folate-dependent cellular processes, although these connections are less directly understood.

**HCP5**: HCP5 plays a crucial role in pharmacogenetics, specifically interacting with abacavir, a drug used in HIV treatment. The hypersensitivity to abacavir is linked to the HCP5-related rs2395029 polymorphism, which affects the expression of the HLA-B*5701 allele, necessitating genetic testing before prescribing the drug to avoid severe adverse reactions. While there are potential interactions with other immune-modulating drugs, such as flucloxacillin and gemcitabine, these are not as clearly defined as the interaction with abacavir.

**SLC22A15**: The gene SLC22A15, from the solute carrier family, is mainly expressed in the brain and testis, suggesting it could potentially influence the pharmacokinetics of neurological medications and drugs affecting reproductive health by affecting their transport across cell membranes. However, there are currently no specific drugs known to interact pharmacogenetically with SLC22A15, leaving its exact role in drug interactions speculative without direct evidence.

**SLC22A11**: The gene SLC22A11 encodes for the organic anion transporter 4 (OAT4), which significantly impacts the renal excretion of drugs such as diuretics like furosemide and thiazide, influencing their effectiveness and potential for toxicity. Alterations in SLC22A11 also affect the clearance of methotrexate, a chemotherapeutic and immunosuppressant agent, primarily through modified drug transport, which could lead to changes in its pharmacokinetic profile despite not directly influencing its metabolism.

**MTRR**: Methotrexate, by inhibiting dihydrofolate reductase, and tegafur, as a prodrug converted to 5-fluorouracil which inhibits thymidylate synthase, both affect folate metabolism, with their impacts potentially moderated or exacerbated based on MTRR gene variants. Supplements like folic acid and leucovorin may counteract these effects by compensating for the inhibition of folate-related enzymes, particularly under the influence of MTRR gene variations.

**TPMT**: The TPMT gene, through genetic variations like TPMT*2, TPMT*3A, and TPMT*3C, plays a significant role in influencing the metabolism of thiopurine drugs including azathioprine, mercaptopurine, and thioguanine. These variations can lead to reduced enzyme activity, thereby increasing the risk of severe myelosuppression if standard doses are used; consequently, dose adjustments based on individual TPMT activity are essential to prevent toxicity and optimize treatment efficacy.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**HLA-E**: The gene HLA-E, which plays a significant role in immune system regulation, may interact pharmacodynamically with methotrexate, a drug used for autoimmune diseases and cancer. This interaction likely occurs as methotrexate modulates immune responses that are under the control of HLA-E, affecting drug efficacy and potential adverse effects rather than affecting the drug's absorption, distribution, metabolism, or excretion.

**SLC28A1**: The gene SLC28A1 encodes a sodium/nucleoside cotransporter that affects the pharmacokinetics of nucleoside analog drugs such as ribavirin, zidovudine, ara-CTP, and gemcitabine by altering their absorption and cellular uptake. This interaction impacts drug concentrations in plasma and thus influences the efficacy and toxicity of therapies, particularly in antiviral and anticancer treatments.

**ADA**: ADA (Adenosine Deaminase) plays a critical role in purine metabolism that affects the pharmacokinetics and pharmacodynamics of several drugs. Specifically, ADA interacts pharmacogenetically with Pegademase bovine (Adagen) to treat ADA-linked Severe Combined Immunodeficiency (SCID) by compensating for the lack of ADA activity and improving clinical outcomes. Furthermore, drugs like azathioprine and 6-mercaptopurine, as well as methotrexate, also interact with ADA, influencing their efficacy and toxicity through mechanisms linked to ADA's enzymatic or cellular metabolic roles.

**ALPL**: Asfotase alfa, a drug used in the management of hypophosphatasia, directly addresses the deficiency caused by mutations in the ALPL gene, which encodes an enzyme essential for bone mineralization. This enzyme replacement therapy (ERT) works by binding to and hydrolyzing substrates in the bone matrix, compensating for the enzyme activity lost due to genetic mutations, and its effectiveness varies based on the specific ALPL mutations present in an individual, highlighting the importance of tailored treatment based on genetic testing.
